Αρχική World News FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer World News FDA Approves Sotorasib with Panitumumab for KRAS G12C-mutated Colorectal Cancer Από Ogkologos - 13 Φεβρουαρίου, 2025 828 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the CodeBreaK 300 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Nivolumab and Relatlimab Combination Shows Promise in Advanced Melanoma 21 Ιουνίου, 2021 Maintenance Regorafenib Significantly Delays Disease Progression After First-Line Treatment in Patients... 28 Απριλίου, 2025 Trastuzumab Deruxtecan Shows Durable Anticancer Activity in Patients with Previously Treated... 28 Ιανουαρίου, 2022 COVID-19 vaccine and cancer – latest updates 20 Νοεμβρίου, 2020 Φόρτωση περισσοτέρων HOT NEWS Daughter Donates Hair to Mother After She Was Diagnosed with Stage... 10 Things Diet Soda Does to Your Body If You Drink... Targeted Radiation Reduces Pain from Cancer Metastases in the Spine High School Students Put Together Fundraiser for Teacher Diagnosed with Breast...